SPA
ALT icon

Sherbrooke Park Advisers’s Altimmune ALT Stock Holding History

Sherbrooke Park Advisers’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$51.1K Sell
14,152
-1,752
-11% -$7.64K 0.13% 168
2025
Q3 		$60K Buy
+15,904
New +$61.4K 0.03% 485

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sherbrooke Park Advisers's ALT Position: Q4 2025 in Review

Sherbrooke Park Advisers reduced its Altimmune (ALT) stake by 11% in Q4 2025, selling an estimated $7.64K and leaving 14,152 shares worth $51.1K. The position accounts for 0.13% of the portfolio, ranked #168.

Sherbrooke Park Advisers first reported a position in ALT in Q3 2025 and has held it in 2 quarters since. The position peaked at $60K in Q3 2025. 181 funds tracked by Wall St. Rank hold ALT as of Q4 2025.

  • Sherbrooke Park Advisers held 14,152 shares of Altimmune worth $51.1K as of Q4 2025.
  • Sherbrooke Park Advisers sold 1,752 Altimmune shares in Q4 2025, an estimated $7.64K.
  • Altimmune made up 0.13% of Sherbrooke Park Advisers's portfolio in Q4 2025, its #168 holding.
  • Sherbrooke Park Advisers first reported a position in Altimmune in Q3 2025 and has held it in 2 quarters since.
  • Sherbrooke Park Advisers's Altimmune position peaked at $60K in Q3 2025.
  • 181 funds tracked by Wall St. Rank held Altimmune as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.